Literature DB >> 16899561

Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma.

Caroline Manhès1, Christine Kayser, Philippe Bertheau, Bruce Kelder, John J Kopchick, Paul A Kelly, Philippe Touraine, Vincent Goffin.   

Abstract

Experimental, clinical, and epidemiological data support the growth-promoting role of endocrine prolactin (PRL) in mammary tumors. PRL is also produced by the breast, where it is now recognized to act as a growth/survival factor via autocrine/paracrine mechanisms. Recent transgenic (Tg) mouse models have revealed the pro-oncogenic effect of PRL over-expression in virgin mammary glands. To address the question whether PRL tumorigenicity was maintained on differentiated mammary glands, we generated mammary-specific Tg mice expressing human (h)PRL under the control of the milk whey acidic protein promoter, which directs autocrine hPRL over-expression in late gestation throughout lactation. Minimal levels of transgene expression were detected in the mammary glands of virgin animals, which at best induced partial ductal branching and lobulo-alveolar structures in older nulliparous females. As expected, expression of mammary hPRL dramatically increased at the end of first pregnancy, and from this point it never returned to baseline, although it peaked at each gestation/lactation cycle. Over-expression of hPRL that starts when the gland is already well into the differentiation process led to various morphological mammary alterations, including abnormally differentiated epithelium, atropy of the myoepithelial layer, dilated ducts, cysts, and lymphocytic infiltrates. These phenotypes tended to worsen with successive pregnancies, also reflecting cumulative damage of failure of involution. Although some older, multiparous females developed benign tumors (papillomas and metaplasias), none of the animals studied developed mammary carcinomas. In addition, we noticed that half of the Tg females exhibited lactation defects, leading to significantly increased pup mortality. This phenotype was due neither to failure of milk production nor to modification of its protein content, but rather it was correlated to lipid enrichment of the milk, which, in combination with profoundly altered morphology of the gland, led to impaired milk extrusion through the nipple. In summary, these data show that over-expression of autocrine hPRL in a differentiating mammary gland induces dramatic functional and morphological defects, but not carcinoma. This deserves further investigations on the emerging concept that autocrine PRL may have different effects on pathological development of the mammary gland depending on the differentiation state of the latter.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16899561     DOI: 10.1677/joe.1.06829

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  14 in total

Review 1.  Benign breast diseases.

Authors:  Carine Courtillot; Geneviève Plu-Bureau; Nadine Binart; Corinne Balleyguier; Brigitte Sigal-Zafrani; Vincent Goffin; Frédérique Kuttenn; Paul A Kelly; Philippe Touraine
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

2.  Modeling prolactin actions in breast cancer in vivo: insights from the NRL-PRL mouse.

Authors:  Kathleen A O'Leary; Michael P Shea; Linda A Schuler
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

3.  Mutation of thyroid hormone receptor-β in mice predisposes to the development of mammary tumors.

Authors:  C J Guigon; D W Kim; M C Willingham; S-Y Cheng
Journal:  Oncogene       Date:  2011-03-14       Impact factor: 9.867

4.  Autocrine prolactin: an emerging market for homegrown (prolactin) despite the imports.

Authors:  Senthil K Muthuswamy
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

5.  Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation.

Authors:  Eric Haines; Parham Minoo; Zhenqian Feng; Nazila Resalatpanah; Xin-Min Nie; Manuela Campiglio; Laura Alvarez; Eftihia Cocolakis; Mohammed Ridha; Mauricio Di Fulvio; Julian Gomez-Cambronero; Jean-Jacques Lebrun; Suhad Ali
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

Review 6.  Rational design of competitive prolactin/growth hormone receptor antagonists.

Authors:  Estelle Tallet; Vincent Rouet; Jean-Baptiste Jomain; Paul A Kelly; Sophie Bernichtein; Vincent Goffin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

Review 7.  Transgenic models to study actions of prolactin in mammary neoplasia.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

8.  Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.

Authors:  Lisa M Arendt; Lindsay C Evans; Debra E Rugowski; Maria Jose Garcia-Barchino; Hallgeir Rui; Linda A Schuler
Journal:  J Endocrinol       Date:  2009-07-27       Impact factor: 4.286

9.  Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.

Authors:  Roman L Bogorad; Carine Courtillot; Chidi Mestayer; Sophie Bernichtein; Lilya Harutyunyan; Jean-Baptiste Jomain; Anne Bachelot; Frédérique Kuttenn; Paul A Kelly; Vincent Goffin; Philippe Touraine
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

Review 10.  What can we learn from rodents about prolactin in humans?

Authors:  Nira Ben-Jonathan; Christopher R LaPensee; Elizabeth W LaPensee
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.